Cite
HARVARD Citation
Weinblatt, M. et al. (2017). A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis & rheumatology. 69 (10), pp. 1937-1948. [Online].